What is platelet-rich plasma or PRP injection cost and is it worth trying? The goal of today’s post is to fact-check PRP based on the scientific literature and educate readers including on PRP cost. What is in this article PRP is getting more popular | Is it worth it? | What exactly is PRP? […]
What is PRP injection cost, risks, & possible benefits Read More »
A solid new, blinded placebo-controlled Phase II study from the Duke Autism Center clearly shows no benefit of cord blood for autism. Surprisingly, the team has said they are encouraged by the results. As a result, they apparently will continue this kind of work anyway despite their data. In contrast, I see the data as a
Duke Autism Center trial: no benefit of cord blood for autism Read More »
Platelet Rich Plasma (PRP) has been around for a long time, but patients are often confused by it. In part the confusion arises from how it is marketed, which sometimes includes it being described as “stem cells”, which it is not. However, at times it can be as a therapy with stem cells or other
Dr. Drew Lansdown Platelet Rich Plasma (PRP) Interview Read More »
The Niche has had many authors over the years, focusing on expertise in the biomedical arena and in particular related to stem cells. I’ve invited many authorities in particular areas to write posts. Over the years I’ve written probably 99+% of the posts here on The Niche, but we’ve also had some great guest authors
Authors on The Niche Read More »
How can we scientists find ways to keep doing our research during the COVID19 pandemic even if it has nothing to do with the coronavirus? Also, how should those of us involved in science communication talk about the outbreak? At a more basic level, how can scientists try not to go bonkers during this dark
Scientists try not to lose it with their labs shut by the pandemic Read More »
It’s been a busy week for the cellular and regenerative medicine space for COVID-19 news with some possible ups including for Mesoblast and some definite downs. Starting with the more positive media buzz with have Mesoblast. Mesoblast made COVID19 news “Thinly traded Mesoblast Limited (NASDAQ:MESO) rockets 51% premarket on average volume in reaction to its announcement of an
COVID-19 cellular medicine buzz: Mesoblast, FTC hammer, more Read More »
Could various kinds of cell therapy help patients with COVID-19? A variety of cell therapies, mostly focused on mesenchymal stromal/stem cells (MSCs), have gotten cleared quickly in the U.S., China, and Israel and possibly other countries to be tested in patients with the novel coronavirus. I hope at least one proves helpful. It’s mostly a
Cell therapy trials for COVID-19 accelerate & some early reports Read More »
To get at addressing what’s the real deal on the idea of cellular therapies for COVID-19, I did a short email Q&A interview with Dr. Sean Morrison. Sean is Chair of the Public Policy Committee at ISSCR and Director of Children’s Research Institute at UT Southwestern. He was also President of ISSCR in 2015-2016, and
Interview with Sean Morrison on cellular therapies for COVID-19 Read More »
When the number of stem cell clinical studies and trials listed for COVID-19 first started spiraling upward it seemed likely that stem cell clinics and other firms in that arena would get interested. I thought that we’d see the unproven regenerative medicine coronavirus bandwagon quickly grow. Unfortunately, there are reasons to be increasingly concerned here. For instance,
As clinics buzz about coronavirus, COVID19 patient given non-FDA-approved exosomes? Read More »
Should we call it stem cell synchronicity for stem cell supplier firm Invitrx? What was it about March 16? Sometimes strange things happen in the stem cell world such as last week on March 16 I wrote that the FDA needs to do more about unproven exosomes, and then on the same day a new FDA warning
‘Captain Kirk’ regenerative clinic supplier Invitrx gets long FDA warning letter Read More »